Stockscreener 앱 받기
2.19
0.92%
0.02
시간 외 거래:
2.19
전일 마감가:
$2.17
열려 있는:
$2.16
하루 거래량:
401.73K
Relative Volume:
0.09
시가총액:
$122.44M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
219.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-4.78%
1개월 성능:
-25.51%
6개월 성능:
+167.60%
1년 성능:
+73.81%
1일 변동 폭
$2.16
$2.225
1주일 범위
$2.11
$2.39
52주 변동 폭
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.19 | 126.36M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics SPRO 2025Q2 Earnings Preview Upside Anticipated on Drug Pipeline Expansion - AInvest
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - The Globe and Mail
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
Biotech Co. AIRNA Adds Ex-Spero Legal Chief As Its 1st CLO - Law360
Spero Therapeutics to Report Second Quarter 2025 Financial - GlobeNewswire
Spero Q2 2025 Earnings: Rare Disease and MDR Treatment Pipeline Updates Coming August 12 - Stock Titan
How does Spero Therapeutics Inc. generate profit in a changing economyGet alerts on high-potential stock breakouts - Jammu Links News
What drives Spero Therapeutics Inc. stock priceInvest confidently with proven investment plans - Jammu Links News
Is Spero Therapeutics Inc. stock overvalued or undervaluedOverwhelming profit margins - Jammu Links News
Is it the right time to buy Spero Therapeutics Inc. stockUnlock superior stock analysis tools - Jammu Links News
Should I hold or sell Spero Therapeutics Inc. stock in 2025Achieve breakthrough investment performance - Jammu Links News
What catalysts could drive Spero Therapeutics Inc. stock higher in 2025Get exclusive access to expert stock recommendations - Jammu Links News
Spero Therapeutics Inc. Stock Analysis and ForecastExceptional trading results - Jammu Links News
What are the latest earnings results for Spero Therapeutics Inc.Exceptional financial outcomes - Jammu Links News
How volatile is Spero Therapeutics Inc. stock compared to the marketTremendous growth potential - Jammu Links News
What institutional investors are buying Spero Therapeutics Inc. stockCapitalize on emerging industry trends - Jammu Links News
How many analysts rate Spero Therapeutics Inc. as a “Buy”Free Smart Trading Workshop - Jammu Links News
Spero Therapeutics Inc. Stock Support and Resistance Levels You Should KnowInvestment Roadmap for High Potential Stocks - Newser
Trend analysis for Spero Therapeutics Inc. this weekSmart Chart Forecasting with AI Algorithms - Newser
How hedge fund analytics apply to Spero Therapeutics Inc. stockPattern Breakout Prediction for Short Term - Newser
Using Python tools to backtest Spero Therapeutics Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
Spero Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingProfit Target Stock Opportunity Monitor Activated - metal.it
Spero Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
What momentum shifts mean for Spero Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
What is the risk reward ratio of investing in Spero Therapeutics Inc. stockPre Market Trend Scanner With High Returns - jammulinksnews.com
How Spero Therapeutics Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Spero Therapeutics Inc. Matches Institutional Buying FilterAccurate Buy Point for Momentum Stocks Detected - metal.it
What makes Spero Therapeutics Inc. stock price move sharplyFree Real Time Stock Movement Analysis - Newser
Multi factor analysis applied to Spero Therapeutics Inc.Free Weekly Setup With 3x Return Potential - Newser
Can Spero Therapeutics Inc. Regain Momentum After BreakdownWeekly Top Gainers Forecast Watchlist Released - beatles.ru
Will Spero Therapeutics Inc. stock benefit from AI tech trendsAI Triggered Buy Zone Forecast System - Newser
Why is Spero Therapeutics Inc. stock attracting strong analyst attentionSwing Trade Review With Proven Results - Jammu Links News
When is Spero Therapeutics Inc. stock expected to show significant growthOutstanding investment returns - Jammu Links News
What is the dividend policy of Spero Therapeutics Inc. stockGet real-time alerts on top-performing stocks - jammulinksnews.com
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):